Taro Pharma (TARO) Misses Q2 EPS by 36c, Approves Special Dividend

Taro Pharma (NYSE: TARO) reported Q2 EPS of $1.60, $0.36 worse than the analyst estimate of $1.96. Revenue for the quarter came in at $159 million versus the consensus estimate of $167.41 million.

Special Dividend Approved by Board of Directors

The Taro Board of Directors has declared a $500 million (or approximately $12.81* per share) special cash dividend on Taro ordinary shares. The special dividend will be paid on December 28, 2018, to shareholders of record at the close of business on December 11, 2018. The ex-dividend date will be December 10, 2018.

Dividend payments distributed by the Company to shareholders will be subject to the withholding of Israeli taxes. Shareholders who are resident in the U.S. or another country that is party to a tax treaty with Israel may be entitled to the release of a portion or all of those Israeli tax amounts withheld. Shareholders will be notified of the procedure to obtain refunds of withheld tax, if applicable, shortly after the record date. Such procedures will also be available on the company’s website at www.taro.com.

For earnings history and earnings-related data on Taro Pharma (TARO) click here.

You May Also Be Interested In

• Pegasystems (PEGA) Declares $0.083 Special Dividend; 0.2% Yield
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August